TVMR With the Innovalve System Trial - First In Human Israel

Last updated: April 18, 2025
Sponsor: Edwards Lifesciences
Overall Status: Completed

Phase

N/A

Condition

Mitral Valve Regurgitation

Treatment

Innovalve MR system

Clinical Study ID

NCT05688514
INVL20-01-IL
  • Ages > 18
  • All Genders

Study Summary

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinically significant, symptomatic mitral regurgitation

  • High risk for open-heart surgery

  • Meets anatomical criteria

Exclusion

Exclusion Criteria:

  • Unsuitable anatomy

  • Patient is inoperable

  • EF<25%

Study Design

Total Participants: 1
Treatment Group(s): 1
Primary Treatment: Innovalve MR system
Phase:
Study Start date:
October 01, 2021
Estimated Completion Date:
April 01, 2025

Study Description

The study is a multi-center, First-In-Human, prospective, single arm early feasibility study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Connect with a study center

  • The Chaim Sheba Medical Center

    Ramat Gan, 5265601
    Israel

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.